**Background**
Schizophrenia is a severe and chronic mental disorder characterized by distortions in thinking, perception, emotions, and behavior. For decades, the primary pharmacological approach to treating schizophrenia has focused on the blockade of dopamine D2 receptors and serotonin 5-HT2A receptors. While effective for positive symptoms, these traditional antipsychotics often lead to significant side effects, including extrapyramidal symptoms and metabolic disturbances. Consequently, there is a critical need for novel therapeutic agents with alternative mechanisms of action that can provide antipsychotic effects without the burden of D2-related adverse events. In this context, we will introduce a unique psychotropic agent – (Rac)-Ulotaront.
**Definition**
(Rac)-Ulotaront (also known as (Rac)-SEP-363856 hydrochloride) is an orally active and CNS-active psychotropic agent that exerts antipsychotic-like effects through a unique, non-D2/5-HT2A mechanism of action.
**In Vitro and In Vivo Studies**
The (Rac)-Ulotaront description highlights its potential as a breakthrough treatment for schizophrenia due to its distinct pharmacological profile. According to the (Rac)-Ulotaront biological activity, this compound does not rely on the traditional dopamine D2 receptor antagonism to achieve its therapeutic effects, thereby potentially reducing the risk of motor side effects. The (Rac)-Ulotaront formula is C9H14ClNOS with a molecular weight of 219.73. Research indicates that (Rac)-Ulotaront is capable of crossing the blood-brain barrier to exert its effects within the central nervous system. In vivo studies have demonstrated that this agent possesses antipsychotic-like properties, supporting its development as a novel treatment for patients with schizophrenia who are unresponsive to or intolerant of current medications. In conclusion, (Rac)-Ulotaront is a novel psychotropic agent that offers a promising non-D2 receptor-based strategy for the treatment of schizophrenia.
Keywords
(Rac)-Ulotaront, 1310422-02-6, (Rac)-SEP-363856, (Rac)-SEP-856, 5-HT Receptor, Serotonin Receptor, 5-hydroxytryptamine Receptor, Inhibitor, inhibitor, inhibit
References